Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT02388490

Study Title
Brentuximab Vedotin in Patients With Relapsed or Refractory EBV-and CD30-positive Lymphomas (Bretuximab) (NCT02388490)

Trial description
This is an open-label, non-randomized, multi-center, phase II trial of brentuximab vedotin (also known as SGN-035) to evaluate ORR primarily in patients with Epstein-Barr virus (EBV)- and CD30-positive lymphomas.

This trial is sponsored by Seoul National University Hospital. [1]

Study data

  • Condition: Lymphoma
  • Interventions:
  • Phase: II
  • Estimated Enrollment: 25
  • Start: April 2015
  • Estimated Completion: June 2017
  • Last verified: March 2015

Study Schematic

(Coming soon)


Last Editorial review: July 2, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.

Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar